Rationale and design of the genomic research in alpha-1 antitrypsin deficiency and sarcoidosis study: Alpha-1 protocol

Annals of the American Thoracic Society

Volumn 12, Issue 10, 2015, Pages 1551-1560

  Strange, Charlie ^a   Senior, Robert M ^b   Sciurba, Frank ^c   O'Neal, Scott ^d   Morris, Alison ^c   Wisniewski, Stephen R ^d   Bowler, Russell ^e   Hochheiser, Harry S ^c   Becich, Michael J ^c   Zhang, Yingze ^c,d   Leader, Joseph K ^c   Methé, Barbara A ^f   Kaminski, Naftali ^g   Sandhaus, Robert A ^e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e DEPARTMENT OF MEDICINE   (United States)

^f J CRAIG VENTER INSTITUTE   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchoalveolar lavage; COPD; Emphysema; Lung; Microbiome; Phenotype

Indexed keywords

ALPHA 1 ANTITRYPSIN; DNA; MICRORNA; PROTEOME; RNA; TRANSCRIPTOME;

ADULT; AGE; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; EXERCISE TOLERANCE; FECES MICROFLORA; FORCED EXPIRATORY VOLUME; GENOME ANALYSIS; GENOTYPE; HUMAN; LOWER RESPIRATORY TRACT; LUNG FUNCTION TEST; LUNG LAVAGE; METABOLOME; MICROBIOME; MONONUCLEAR CELL; PHENOTYPE; PROSPECTIVE STUDY; PROTEOMICS; SARCOIDOSIS; SYMPTOMATOLOGY; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; VIROLOGY; VIROME; AGED; ALPHA 1-ANTITRYPSIN DEFICIENCY; CLINICAL TRIAL; FEMALE; GENOMICS; MALE; METHODOLOGY; MICROFLORA; MIDDLE AGED; MULTICENTER STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTITRYPSIN DEFICIENCY; BRONCHOALVEOLAR LAVAGE; CROSS-SECTIONAL STUDIES; EXERCISE TOLERANCE; FEMALE; GENOMICS; GENOTYPE; HUMANS; MALE; MICROBIOTA; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84943602660     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201503-143OC     Document Type: Article

References (65)

1. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of a1-antitrypsin deficiency: a continuing problem. Chest 2005;128:1989-1994.
2. McElvaney NG, Stoller JK, Buist AS, Prakash UB, Brantly ML, Schluchter MD, Crystal RD; a1-Antitrypsin Deficiency Registry Study Group. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of a1-antitrypsin deficiency. Chest 1997;111:394-403.
3. Eden E, Strange C, Holladay B, Xie L. Asthma and allergy in a-1 antitrypsin deficiency. Respir Med 2006;100:1384-1391.
4. Needham M, Stockley RA. Exacerbations in a1-antitrypsin deficiency. Eur Respir J 2005;25:992-1000.
5. Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in a1-antitrypsin deficiency. Am J Respir Crit Care Med 2002;165:1494-1498.
6. Mohanka M, Khemasuwan D, Stoller JK. A review of augmentation therapy for a-1 antitrypsin deficiency. Expert Opin Biol Ther 2012;12: 685-700.
7. Stockley RA, Hill AT, Hill SL, Campbell EJ. Bronchial inflammation: its relationship to colonizing microbial load and a1-antitrypsin deficiency. Chest 2000; 117(5 Suppl 1)291S-293S.
8. Novoradovsky A, Brantly ML, Waclawiw MA, Chaudhary PP, Ihara H, Qi L, Eissa NT, Barnes PM, Gabriele KM, Ehrmantraut ME, et al. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in a1-antitrypsin deficiency. Am J Respir Cell Mol Biol 1999;20:441-447.
9. Rodriguez F, de la Roza C, Jardi R, Schaper M, Vidal R, Miravitlles M. Glutathione S-transferase P1 and lung function in patients with a1-antitrypsin deficiency and COPD. Chest 2005;127:1537-1543.
10. Dawkins PA, Dowson LJ, Guest PJ, Stockley RA. Predictors of mortality in a1-antitrypsin deficiency. Thorax 2003;58:1020-1026.
11. Wood AM, Needham M, Simmonds MJ, Newby PR, Gough SC, Stockley RA. Phenotypic differences in a1 antitrypsin-deficient sibling pairs may relate to genetic variation. COPD 2008;5:353-359.
12. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z a1-antitrypsin accumulation in the liver. Nature 1992;357:605-607.
13. Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, Stockley RA. Exploring the role of CT densitometry: a randomised study of augmentation therapy in a1-antitrypsin deficiency. Eur Respir J 2009;33:1345-1353.
14. Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, et al.; RAPID Trial Study Group. Intravenous augmentation treatment and lung density in severe a1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015;386:360-368.
15. Molloy K, Hersh CP, Morris VB, Carroll TP, OConnor CA, Lasky-Su JA, Greene CM, ONeill SJ, Silverman EK, McElvaney NG. Clarification of the risk of chronic obstructive pulmonary disease in a1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014; 189:419-427.
16. Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in a1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004;59:843-849.
17. Lieberman J, Winter B, Sastre A. a1-Antitrypsin Pi-types in 965 COPD patients. Chest 1986;89:370-373.
18. Cuvelier A, Muir JF, Hellot MF, Benhamou D, Martin JP, Bénichou J, Sesboüé R. Distribution of a1-antitrypsin alleles in patients with bronchiectasis. Chest 2000;117:415-419.
19. Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in a1-antitrypsin deficiency. Am J Respir Crit Care Med 2007;176:1215-1221.
20. Tomashefski JF Jr, Crystal RG, Wiedemann HP, Mascha E, Stoller JK; Alpha 1-Antitrypsin Deficiency Registry Study Group. The bronchopulmonary pathology of a-1 antitrypsin (AAT) deficiency: findings of the Death Review Committee of the national registry for individuals with severe deficiency of alpha-1 antitrypsin. Hum Pathol 2004;35:1452-1461.
21. Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, Bushman FD, Collman RG. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011;184:957-963.
22. Morris A, Beck JM, Schloss PD, Campbell TB, Crothers K, Curtis JL, Flores SC, Fontenot AP, Ghedin E, Huang L, et al.; Lung HIV Microbiome Project. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med 2013; 187:1067-1075.
23. Gleeson K, Eggli DF, Maxwell SL. Quantitative aspiration during sleep in normal subjects. Chest 1997;111:1266-1272.
24. Lozupone C, Cota-Gomez A, Palmer BE, Linderman DJ, Charlson ES, Sodergren E, Mitreva M, Abubucker S, Martin J, Yao G, et al.; Lung HIV Microbiome Project. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med 2013;187:1110-1117.
25. Murphy TF, Sethi S, Hill SL, Stockley RA. Inflammatory markers in bacterial exacerbations of COPD. Am J Respir Crit Care Med 2002; 165:132.
26. Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177: 491-497.
27. Dickson RP, Erb-Downward JR, Freeman CM, Walker N, Scales BS, Beck JM, Martinez FJ, Curtis JL, Lama VN, Huffnagle GB. Changes in the lung microbiome following lung transplantation include the emergence of two distinct Pseudomonas species with distinct clinical associations. PLoS One 2014;9:e97214.
28. Taylor SL, Rogers GB, Chen AC, Burr LD, McGuckin MA, Serisier DJ. Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. Ann Am Thorac Soc 2015;12:701-707.
29. Iwai S, Huang D, Fong S, Jarlsberg LG, Worodria W, Yoo S, Cattamanchi A, Davis JL, Kaswabuli S, Segal M, et al. The lung microbiome of Ugandan HIV-infected pneumonia patients is compositionally and functionally distinct from that of San Franciscan patients. PLoS One 2014;9:e95726.
30. Sethi S, Mallia P, Johnston SL. New paradigms in the pathogenesis of chronic obstructive pulmonary disease II. Proc Am Thorac Soc 2009; 6:532-534.
31. Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:266-272.
32. Wilkinson TM, Donaldson GC, Johnston SL, Openshaw PJ, Wedzicha JA. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:871-876.
33. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, Rogers RM, Hayashi S, Hogg JC. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001;164:469-473.
34. Morris A, Sciurba FC, Lebedeva IP, Githaiga A, Elliott WM, Hogg JC, Huang L, Norris KA. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004;170:408-413.
35. Sze MA, Utokaparch S, Elliott WM, Hogg JC, Hegele RG. Loss of GD1-positive Lactobacillus correlates with inflammation in human lungs with COPD. BMJ Open 2015;5:e006677.
36. Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. Chronic obstructive pulmonary disease lung microbiota diversity may be mediated by age or inhaled corticosteroid use. J Clin Microbiol 2015; 53:1050.
37. Kim JS, Tanaka N, Newell JD, Degroote MA, Fulton K, Huitt G, Lynch DA. Nontuberculous mycobacterial infection: CT scan findings, genotype, and treatment responsiveness. Chest 2005;128:3863-3869.
38. Shapiro L, Pott GB, Ralston AH. Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB J 2001;15:115-122.
39. Hubbard RC, Fells G, Gadek J, Pacholok S, Humes J, Crystal RG. Neutrophil accumulation in the lung in a1-antitrypsin deficiency: spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991;88:891-897.
40. Tan L, Dickens JA, Demeo DL, Miranda E, Perez J, Rashid ST, Day J, Ordoñez A, Marciniak SJ, Haq I, et al. Circulating polymers in a1-antitrypsin deficiency. Eur Respir J 2014;43:1501-1504.
41. Bergin DA, Reeves EP, Meleady P, Henry M, McElvaney OJ, Carroll TP, Condron C, Chotirmall SH, Clynes M, ONeill SJ, et al. a-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest 2010;120:4236-4250.
42. Mahadeva R, Atkinson C, Li Z, Stewart S, Janciauskiene S, Kelley DG, Parmar J, Pitman R, Shapiro SD, Lomas DA. Polymers of Z a1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005;166:377-386.
43. Mulgrew AT, Taggart CC, Lawless MW, Greene CM, Brantly ML, ONeill SJ, McElvaney NGZ. Z a1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest 2004;125:1952-1957.
44. Wencker M, Brantly ML. Cytotoxic concentrations of a-defensins in the lungs of individuals with a1-antitrypsin deficiency and moderate to severe lung disease. Cytokine 2005;32:1-6.
45. Houghton AM, Quintero PA, Perkins DL, Kobayashi DK, Kelley DG, Marconcini LA, Mecham RP, Senior RM, Shapiro SD. Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest 2006;116:753-759.
46. Carroll TP, Greene CM, OConnor CA, Nolan AM, ONeill SJ, McElvaney NG. Evidence for unfolded protein response activation in monocytes from individuals with a-1 antitrypsin deficiency. J Immunol 2010;184:4538-4546.
47. Schaaf B, Wieghorst A, Aries SP, Dalhoff K, Braun J. Neutrophil inflammation and activation in bronchiectasis: comparison with pneumonia and idiopathic pulmonary fibrosis. Respiration 2000;67:52-59.
48. Chan SC, Shum DK, Ip MS. Sputum sol neutrophil elastase activity in bronchiectasis: differential modulation by syndecan-1. Am J Respir Crit Care Med 2003;168:192-198.
49. Chan SC, Leung VO, Ip MS, Shum DK. Shed syndecan-1 restricts neutrophil elastase from a1-antitrypsin in neutrophilic airway inflammation. Am J Respir Cell Mol Biol 2009;41:620-628.
50. Baraldo S, Turato G, Lunardi F, Bazzan E, Schiavon M, Ferrarotti I, Molena B, Cazzuffi R, Damin M, Balestro E, et al. Immune activation in a1-antitrypsin-deficiency emphysema: beyond the protease-antiprotease paradigm. Am J Respir Crit Care Med 2015;191: 402-409.
51. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
52. Carp H, Miller F, Hoidal JR, Janoff A. Potential mechanism of emphysema: a1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci USA 1982;79: 2041-2045.
53. Vogelmeier C, Biedermann T, Maier K, Mazur G, Behr J, Krombach F, Buhl R. Comparative loss of activity of recombinant secretory leukoprotease inhibitor and a1-protease inhibitor caused by different forms of oxidative stress. Eur Respir J 1997;10: 2114-2119.
54. Abrams WR, Fein AM, Kucich U, Kueppers F, Yamada H, Kuzmowycz T, Morgan L, Lippmann M, Goldberg SK, Weinbaum G. Proteinase inhibitory function in inflammatory lung disease: I. Acute bacterial pneumonia. Am Rev Respir Dis 1984;129:735-741.
55. Ossanna PJ, Test ST, Matheson NR, Regiani S, Weiss SJ. Oxidative regulation of neutrophil elastase-a-1-proteinase inhibitor interactions. J Clin Invest 1986;77:1939-1951.
56. Kindt GC, Weiland JE, Davis WB, Gadek JE, Dorinsky PM. Bronchiolitis in adults: a reversible cause of airway obstruction associated with airway neutrophils and neutrophil products. Am Rev Respir Dis 1989; 140:483-492.
57. ORiordan TG, Otero R, Mao Y, Lauredo I, Abraham WM. Elastase contributes to antigen-induced mucociliary dysfunction in ovine airways. Am J Respir Crit Care Med 1997;155:1522-1528.
58. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2014; accessed 2015 Jul 27]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD-Report2014-Feb07.pdf.
59. Couper D, LaVange LM, Han M, Barr RG, Bleecker E, Hoffman EA, Kanner R, Kleerup E, Martinez FJ, Woodruff PG, et al.; SPIROMICS Research Group. Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax 2014;69:491-494.
60. Strange C, Dickson R, Carter C, Carpenter MJ, Holladay B, Lundquist R, Brantly ML. Genetic testing for a1-antitrypsin deficiency. Genet Med 2004;6:204-210.
61. Victoria JG, Kapoor A, Dupuis K, Schnurr DP, Delwart EL. Rapid identification of known and new RNA viruses from animal tissues. PLoS Pathog 2008;4:e1000163.
62. Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F, Gordon JI. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 2010;466:334-338.
63. Thurber RV, Haynes M, Breitbart M, Wegley L, Rohwer F. Laboratory procedures to generate viral metagenomes. Nat Protoc 2009;4: 470-483.
64. Huang GT, Athanassiou C, Benos PV. mirConnX: condition-specific mRNA-microRNA network integrator. Nucleic Acids Res 2011;39 (Web Server issue):W416-W423.
65. Li K, Bihan M, Methé BA. Analyses of the stability and core taxonomic memberships of the human microbiome. PLoS One 2013;8:e63139.